PMID- 15210399
OWN - NLM
STAT- MEDLINE
DCOM- 20040729
LR  - 20131121
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 9
IP  - 4
DP  - 2004 Apr 30
TI  - Anticoagulation with low-molecular-weight heparin in patients with heart 
      diseases.
PG  - 186-98
AB  - Low-molecular-weight heparins (LMWH) were investigated in different cardiac 
      diseases requiring anticoagulation. In case of short term usage advantages over 
      intravenous unfractionated heparin (UFH) are of relevance, such as simple 
      subcutaneous application, possibility for outpatient treatment and predictable 
      effect on anticoagulation enabling abstention of laboratory monitoring in most 
      cases. Thromboprophylaxis in acute medically ill patients and therapy of 
      non-ST-elevation acute coronary syndromes (NSTE-ACS) are important indications, 
      in which significant advantages for special LMWH as compared to Placebo or UFH 
      were shown. A significant effect versus Placebo was demonstrated for the LMWH 
      Dalteparin in prolonged anticoagulation until revascularisation procedure in 
      NSTE-ACS. Promising results from trials were also published concerning use of 
      LMWH Dalteparin and Enoxaparin in TEE-guided cardioversion. Findings from cohort 
      trials are available for temporary or long term switch from oral anticoagulation 
      to LMWH. Due to limited data, determination of individual benefit-to-risk ratio 
      is of special importance to select suitable anticoagulation regimen in this case. 
      Further investigations as a basis of general recommendations on standard dosing 
      regimen are outstanding for use of each LMWH in percutaneous coronary 
      interventions, as combination with Glycoprotein IIb/IIIa-inhibitors, in acute 
      myocardial infarction and in artificial heart valves. In cardiology, most studies 
      were performed with Dalteparin and Enoxaparin, suggesting these to be used in 
      established cardiac indications as well as in further investigations.
FAU - Bechtold, H
AU  - Bechtold H
AD  - Department of Internal Medicine, Regional Hospital of Crailsheim, Germany. 
      heinrich.bechtold@t-online.de
FAU - Janssen, D
AU  - Janssen D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Atrial Fibrillation/drug therapy
MH  - Dalteparin/therapeutic use
MH  - Enoxaparin/therapeutic use
MH  - Heart Diseases/*therapy
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Thromboembolism/drug therapy
RF  - 110
EDAT- 2004/06/24 05:00
MHDA- 2004/07/30 05:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/07/30 05:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
PST - ppublish
SO  - Eur J Med Res. 2004 Apr 30;9(4):186-98.